Key statistics
On Friday, Arcturus Therapeutics Holdings Inc (ARCT:NMQ) closed at 20.61, 17.64% above the 52 week low of 17.52 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 20.88 |
---|---|
High | 21.50 |
Low | 20.39 |
Bid | 20.30 |
Offer | 21.25 |
Previous close | 21.02 |
Average volume | 416.88k |
---|---|
Shares outstanding | 27.04m |
Free float | 24.75m |
P/E (TTM) | -- |
Market cap | 557.34m USD |
EPS (TTM) | -2.68 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
- Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis
- Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
- Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress
- Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference
- Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
- Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
More ▼